Cellular Fibronectin as a Tumor Marker
Author Information
Author(s): C Haglund, S Ylatupa, P Mertaniemi, P Partanen
Primary Institution: University of Helsinki
Hypothesis
Can cellular fibronectin (cFN) levels in plasma serve as a reliable tumor marker for malignant and benign diseases?
Conclusion
The new cFN test shows promise as a tumor marker, particularly for colorectal cancer and hepatocellular carcinoma.
Supporting Evidence
- cFN levels were higher in plasma than in serum.
- cFN showed a sensitivity of 72% compared to 61% for alpha-fetoprotein.
- Combination of cFN and CA 19-9 increased sensitivity to 47%.
Takeaway
This study looked at a new test that measures a substance called cellular fibronectin in the blood to help doctors find cancer. It works better for some types of cancer than others.
Methodology
Plasma and serum samples were collected from patients, and cFN levels were measured using an enzyme immunoassay.
Limitations
The study included only preoperative data and had a small number of patients in some diagnosis groups.
Participant Demographics
261 patients with malignant diseases and 207 patients with benign diseases.
Statistical Information
P-Value
0.003
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website